Stevanato Group S.p.A. STVN
Set alert
At close · Nov 2
After hours · Nov 2, 4:02 PM ET
- YTD
- -1.89%
- 1 year
- -21.73%
- Open
- 19.62
- Prev close
- 19.38
- Mkt cap
- 5.39B
- Vol
- 772.34K
- Avg vol
- 394.49K
- EPS
- 0.57
- P/E
- 34.63
- Div yield
- 0.32%
More statistics
- Low
- 19.47
- High
- 20.26
- Forward P/E
- 23.99
- Beta
- 0.80
- Short ratio
- 3.04
- Inst. own
- 102.96%
- Dividend
- 0.06
- Ex-div date
- Jun 10, 2026
- Earnings
- Nov 3, 2026
- 50-d avg
- 20.58
- 200-d avg
- 18.10
- 1y target
- 24.84
3M chart
Events in this range
- Aug 4, 2026Earnings: 0.16; estimate 0.1448; surprise 10.5%
- Sep 9, 2026Rating: UBS · Neutral → Neutral
Signals (15)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 3 days ago |
| SMA: Bullish | Oct 29, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Sep 30, 2026 | 1 month ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 24, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 16, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| RSI: Overbought | Aug 20, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 11, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 4, 2026 | 3 months ago |
Key statistics
- Market cap
- 5.40B
- Enterprise value
- 5.66B
- Trailing P/E
- 34.73
- Forward P/E
- 23.99
- PEG ratio
- 1.38
- Price / sales
- 4.41
- Price / book
- 3.11
- EPS (TTM)
- 0.57
- Beta
- 0.80
- Dividend yield
- 0.32%
- Payout ratio
- 11.02%
- Profit margin
- 10.99%
- Revenue (TTM)
- 1.23B
- Revenue growth
- 7.80%
- Free cash flow
- -104.70M
- Total cash
- 79.14M
- Total debt
- 445.30M
- Return on equity
- 9.13%
- Shares outstanding
- 49.71M
- Short % of float
- 1.97%
- 50-day average
- 20.58
- 200-day average
- 18.10
Analyst view
Consensus: buy
- Target (low)
- 21.00
- Target (mean)
- 24.84
- Target (high)
- 32.00
- Strong buy2
- Buy7
- Hold4
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate 0.1776.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | 0.1775 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | 0.1448 | 0.16 | +0.02 | +10.50% |
| May 7, 2026 | Mar 31, 2026 | 0.12 | 0.13 | +0.01 | +8.33% |
| Mar 4, 2026 | Dec 31, 2025 | 0.20 | 0.21 | +0.01 | +5.00% |
| Nov 6, 2025 | Sep 30, 2025 | 0.14 | 0.16 | +0.02 | +14.29% |
| Aug 5, 2025 | Jun 30, 2025 | 0.11 | 0.12 | +0.01 | +9.09% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 2026 | UBS | main | Neutral | Neutral |
| Jun 16, 2026 | TD Cowen | init | — | Buy |
| Mar 6, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Mar 5, 2026 | Citigroup | main | Buy | Buy |
| Mar 5, 2026 | Keybanc | main | Overweight | Overweight |
| Dec 2, 2025 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About Stevanato Group S.p.A.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- Italy
- Website
- stevanatogroup.com
News
- Conestoga Small Cap Composite Q3 2026 Portfolio Activity
- Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
- Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update
- Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026
- Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- UBS Maintains Neutral on Stevanato Group, Lowers Price Target to $23
- Stevanato Group to Participate in Two Upcoming Investor Conferences
- A Look at Stevanato Group SpA (STVN) After 3.4% Decline -- GF Value $25.98 vs Price $20.71
- Stevanato Group: Alina Validates The Container-To-Device Flywheel
- Stevanato Group SpA (STVN) Shares Fall 5.7% -- What GF Score of 87 Tells Investors
Your note
Sign in to keep a note on STVN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BALACHANDRAN MADHAVEN | Director | Sale | Jun 14, 2026 | 69,458 |
| DAL LAGO MARCO | Chief Financial Officer | Sale | Aug 6, 2026 | 81,144 |
| FEDERICI WILLIAM J | Director | Sale | Jun 14, 2026 | 58,580 |
| FLYNN KAREN A | Director | Sale | Jun 14, 2026 | 5,757 |
| LIN SUE-JEAN | Director | Stock Award(Grant) | Jun 11, 2026 | 6,975 |
| MAGISTRETTI ELISABETTA | Director | Sale | Aug 6, 2026 | 2,930 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Conestoga Capital Advisors, LLC | 2.31% | 7,007,613 | 138.72M | Jun 29, 2026 |
| Neuberger Berman Group, LLC | 1.86% | 5,622,269 | 111.29M | Jun 29, 2026 |
| Times Square Capital Management, LLC | 1.15% | 3,474,641 | 68.78M | Jun 29, 2026 |
| Van Berkom & Associates Inc. | 0.98% | 2,969,220 | 58.78M | Jun 29, 2026 |
| Artisan Partners Limited Partnership | 0.86% | 2,601,598 | 51.50M | Jun 29, 2026 |
| BAMCO Inc. | 0.82% | 2,494,871 | 49.39M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Conestoga Funds-Conestoga Small Cap Fund | 1.15% | 3,484,751 | 68.98M | Jun 29, 2026 |
| NEUBERGER BERMAN EQUITY FUNDS-Neuberger Genesis Fund | 1.00% | 3,041,141 | 60.20M | Sep 29, 2026 |
| BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd. | 0.56% | 1,681,429 | 33.28M | Jun 29, 2026 |
| Artisan Partners Funds Inc.-Artisan Small Cap Fund | 0.28% | 837,773 | 16.58M | Jun 29, 2026 |
| AMG Funds-AMG TimesSquare Mid Cap Growth Fund | 0.22% | 653,137 | 12.93M | Jun 29, 2026 |
| Conestoga Funds-Conestoga SMid Cap Fund | 0.20% | 596,192 | 11.80M | Jun 29, 2026 |